#JPM26: Regeneron, Lilly, Summit on rivals crowding into same targets
#JPM26：再生元、礼来、Summit Therapeutics谈竞争者扎堆同一靶点

There are countless diseases lacking a single good treatment, but drugmakers are still herding into the same targets, particularly in chasing after megablockbusters.
无数疾病至今缺乏哪怕一种像样的疗法，但制药商仍一窝蜂涌向相同的靶点，尤其热衷追逐超级重磅药。